Looking for New Urine Markers to Screen for Prostate Cancer
Collects urine samples from men to study new markers for detecting prostate cancer.
Plain-language title generated from the registry record
Registry title: To Identify Potential New Urine Markers for the Screening of Prostate Cancer
Key facts
- Where
- Shatin, Hong KongSee the site
Where in Hong Kong
- Prince of Wales HospitalShatin, Hong KongTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chinese University of Hong Kong
- Trial code
- NCT03914391
- Record updated
- 27 October 2026
- Original description
Prostate gland is a clinically important male sexual organ and its main function is for the production of semen. Globally, it is the second most common cancer in men globally and is also the fifth cancer cause for death in male. Despite the improvement in the understanding of prostate cancer, the current usage of serum prostate specific antigen (PSA) as a diagnostic marker is still not ideal. Many patients with elevated PSA and then subjected to prostate biopsy were found to have no prostate cancer. Therefore, there is a need to discover new biological markers to improve the current situation in diagnosis and also management of prostate cancer.Read full original descriptionShow less
To Identify Potential New Urine Markers for the Screening of Prostate Cancer
Prostate gland is a clinically important male sexual organ and its main function is for the production of semen. Globally, it is the second most common cancer in men globally and is also the fifth cancer cause for death in male. Despite the improvement in the understanding of prostate cancer, the current usage of serum prostate specific antigen (PSA) as a diagnostic marker is still not ideal. Many patients with elevated PSA and then subjected to prostate biopsy were found to have no prostate cancer. Therefore, there is a need to discover new biological markers to improve the current situation in diagnosis and also management of prostate cancer.
From the earlier small-scale studies, urinary spermine levels have been shown to correlate well with prostate cancer diagnosis and cancer aggressiveness. Due to its nature, it could provide a more convenient and non-invasive method for detecting prostate cancer. The purpose of this study was to collect urine samples to study the role of potential new urine diagnostic markers (including Spermine and others) for prostate cancer diagnosis.
Inclusion: Adult male patients with age > 18 years old; Subject has elevated serum PSA level above 4ng/ml; Clinical planned for prostatic biopsy.
Exclusion: Patient with recent urinary tract infection within 6 weeks prior to PSA testing and urine collection; Patient with recent urethral instrumentation, such as Foley catheter insertion, cystoscopy etc, within 6 weeks prior to PSA testing and urine collection; Patient with consumption of 5 alpha reductase inhibitors in past 6 months; Patient did not receive any surgery for prostatic pathology; Patient refused or unable to provide consent for the study.